A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor.
A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor. Robert Dawson AP
A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor. Robert Dawson AP